atheroprevent - I don't think people here are expecting a buyout, I think they are saying they'd like to see one.
I honestly don't think there's any question at all that there would be multiple buyers interested in Cortex.
The potential is too large, too many BPs have patent life issues on their blockbusters and have weak pipelines to replace them, the CX717 ADHD trial results still stand as a major proof of concept, several BPs have their own Ampakine programs and Cortex's program by far is the most advanced and promising, and Cortex has an incredible stranglehold on the IP surrounding Ampakines.
All of the above translates into no problem selling the company IMO, it's just a matter of what the price might end up at.
I can't conceive of the price ever coming close to the true potential value of the Ampakine program, so my preference is to see Cortex try to come up with a creative arrangement that allows them to remain independent for a while longer, and pursue their in-house programs while a BP partner handles everything else. See #Msg-23673914 for my high level thoughts about such a deal.
News 
Market Data 
Discover 
